Sugi Predict

Sugi Predict / Compounds / SCHEMBL1600169

SCHEMBL1600169

SCHEMBL1600169

Nc1cnc2ccc(Br)cc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 2/20 0.57
▸ PABPC1 P11940 1/20 0.48
▸ HTT P42858 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ PIK3R1 P27986 1/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ EGFR P00533 2/20 0.37
▸ MMP2 P08253 1/20 0.37
▸ MMP9 P14780 1/20 0.37
▸ MMP8 P22894 1/20 0.37
▸ MMP13 P45452 1/20 0.37
▸ APP P05067 1/20 0.37
▸ ALOX5AP P20292 1/20 0.36
▸ FEN1 P39748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29987438 1.00 BACE1 (0.57) BACE1PABPC1HTTCYP1A2CYP2C19
SCHEMBL1598483 0.92 BACE1 (0.57) BACE1PABPC1HTTCYP1A2CYP2C19
SCHEMBL1932280 0.84 BACE1 (0.57) BACE1PABPC1HTTKMT2AEGFR
SCHEMBL26919701 0.79 HTT (0.44) BACE1PABPC1HTTCYP1A2CYP2C19
SCHEMBL14791619 0.79 PLAU (0.52) HTTKDM4EMEN1ALDH1A1MAPT
SCHEMBL23093847 0.77 PABPC1 (0.39) BACE1PABPC1HTTCYP1A2CYP2C19
SCHEMBL29688067 0.77 PABPC1 (0.39) BACE1PABPC1HTTCYP1A2CYP2C19
SCHEMBL6845013 0.76 BACE1 (0.55) BACE1CYP1A2KDM4EMEN1ALDH1A1
SCHEMBL15150158 0.76 HTT (0.41) BACE1PABPC1HTTCYP1A2CYP2C19
SCHEMBL797784 0.76 HTT (0.41) BACE1PABPC1HTTCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116535389-B 6-Pyridine-3-quinoxaline urea derivative and application thereof 四川大学 2024-05-03 — — CN disclosed
US-11926632-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2024-03-12 — — US disclosed
CN-114605391-B Quinoxaline derivative, preparation method and application thereof 广州六顺生物科技股份有限公司 2024-01-26 — — CN disclosed
EP-3567041-B1 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF IMPACT THERAPEUTICS SHANGHAI INC (CN) 2023-12-27 — — EP disclosed
US-20230330127-A1 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-19 — — US disclosed
EP-3980417-B1 PRMT5 INHIBITORS LUPIN LTD (IN) 2023-09-27 — — EP disclosed
CN-116535389-A 6-pyridine-3-quinoxaline urea derivative and application thereof 四川大学 2023-08-04 — — CN disclosed
EP-4219496-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
EP-4167982-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-04-26 — — EP disclosed
CN-110167941-B Substituted fused heteroaryl compounds as kinase inhibitors and uses thereof 上海瑛派药业有限公司 2023-04-04 — — CN disclosed
US-20190263806-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME DOOSAN CORPORATION (KR) 2019-08-29 — — US disclosed
EP-2560967-B1 Heterocyclic carboxylic acid amides as PDK1 inihibitors BOEHRINGER INGELHEIM INT (DE) 2017-12-20 — — EP disclosed
WO-2017032840-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 — — WO disclosed
US-20110112106-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2011-05-12 — — US disclosed
US-7919621-B2 Tricyclic inhibitors of 5-lipoxygenase AMIRA PHARMACEUTICALS, INC. (US) 2011-04-05 — — US disclosed
EP-1978966-A2 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE Amira Pharmaceuticals, Inc. (US) 2008-10-15 — — EP disclosed
WO-2008015423-A1 QUINOLINE AND QUINOXALINE N-OXIDES AS CHK-1 INHIBITORS SENTINEL ONCOLOGY LIMITED (GB) 2008-02-07 — — WO disclosed
WO-2008015423-A1 QUINOLINE AND QUINOXALINE N-OXIDES AS CHK-1 INHIBITORS SENTINEL ONCOLOGY LIMITED (GB) 2008-02-07 — — WO disclosed
WO-2007087250-A2 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-08-02 — — WO disclosed
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE ALOX5, ALOX15, ALOX15B BACE1 2373/4885PABPC1 2401/4885HTT 3512/4885
US-20110112106-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE ALOX5, ALOX15, ALOX15B BACE1 2373/4885PABPC1 2401/4885HTT 3512/4885
US-20230330127-A1 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 BACE1 2092/4885PABPC1 361/4885HTT 3966/4885
US-11926632-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS BACE1 4301/4885PABPC1 650/4885HTT 2757/4885
US-20190263806-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME VDAC1, OR10J3, VDAC2 BACE1 1080/4885PABPC1 4206/4885HTT 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.